JAK1 and histiocytic sarcoma: In conclusion, based on findings observed in skin biopsies and blood of patients with moderate-to-severe HS, 8 weeks of treatment with the JAK1 inhibitor povorcitinib was associated with the reversal of a previously identified HS transcriptomic signature, as well as dose-dependent changes in a number of circulating proteins that may contribute to disease pathology.